Biosensors launches DES with biodegradable polymer in Europe
Biosensors International Group has launched its BioMatrix drug-eluting stent (DES) system in European markets, as well as in the Middle East, Africa and Asia.
BioMatrix is a DES system that combines a biodegradable polymer and its proprietary limus drug, Biolimus A9, according to the Singapore-based company.
Biosensors received CE Mark for BioMatrix in January.
Along with the commercial launch, Biosensors said it has begun enrollment in a patient registry to collect five-year data on the safety and efficacy of BioMatrix in up to 5,000 patients.
BioMatrix is a DES system that combines a biodegradable polymer and its proprietary limus drug, Biolimus A9, according to the Singapore-based company.
Biosensors received CE Mark for BioMatrix in January.
Along with the commercial launch, Biosensors said it has begun enrollment in a patient registry to collect five-year data on the safety and efficacy of BioMatrix in up to 5,000 patients.